Coronavirus
AstraZeneca vaccine booster shot effective against omicron: Oxford lab study
A three-dose course of AstraZeneca’s COVID-19 vaccine is effective against the omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against imicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from COVID-19.
For all the latest headlines follow our Google News channel online or via the app.
After a three-dose course of the vaccine, neutralizing levels against omicron were similar to those against the virus’s delta variant after two doses, the company added.
The Anglo-Swedish drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine, Vaxzevria, with AstraZeneca.
Read more:
Omicron hospitalization risk is far below delta’s in two studies
Pfizer pill becomes first US-authorized home COVID-19 treatment
Also Read
-
Omicron hospitalization risk is far below delta’s in two studies
The omicron variant of Covid-19 may be less likely to land patients in the hospital than the delta strain, according to a trio of studies of ... Coronavirus -
Australian states reinstate COVID-19 curbs as omicron cases jump
Australia’s two most populous states re-introduced COVID-19 curbs on Thursday as daily infections hit their highest amid an outbreak of the highly ... Coronavirus -
Olympics: China expects COVID cases due to Games arrivals, flags omicron risk
Organizers of the Beijing Winter Olympics said on Thursday they expect a “certain number” of COVID-19 cases in China due to foreigners arriving for ... World News
